Phreesia (PHR) – Investment Analysts’ Weekly Ratings Changes

Several brokerages have updated their recommendations and price targets on shares of Phreesia (NYSE: PHR) in the last few weeks:

• 1/10/2025 – Phreesia had its price target raised by analysts at Citigroup Inc. from $31.00 to $35.00. They now have a “buy” rating on the stock.
• 1/10/2025 – Phreesia had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.
• 1/8/2025 – Phreesia had its price target raised by analysts at KeyCorp from $28.00 to $30.00. They now have an “overweight” rating on the stock.
• 1/8/2025 – Phreesia was upgraded by analysts at Royal Bank of Canada from a “sector perform” rating to an “outperform” rating. They now have a $32.00 price target on the stock, up previously from $24.00.
• 12/11/2024 – Phreesia had its price target lowered by analysts at Robert W. Baird from $34.00 to $30.00. They now have an “outperform” rating on the stock.
• 12/11/2024 – Phreesia had its price target raised by analysts at Truist Financial Co. from $31.00 to $34.00. They now have a “buy” rating on the stock.
• 12/10/2024 – Phreesia had its “market outperform” rating reaffirmed by analysts at JMP Securities. They now have a $30.00 price target on the stock.
• 12/10/2024 – Phreesia had its “buy” rating reaffirmed by analysts at Needham & Company LLC. They now have a $29.00 price target on the stock.

Phreesia Stock Performance

NYSE:PHR traded up $0.07 during mid-day trading on Tuesday, hitting $27.28. The stock had a trading volume of 239,499 shares, compared to its average volume of 366,081. The company has a 50 day simple moving average of $23.65 and a 200-day simple moving average of $22.89. The stock has a market capitalization of $1.59 billion, a price-to-earnings ratio of -18.56 and a beta of 0.94. The company has a current ratio of 1.74, a quick ratio of 1.74 and a debt-to-equity ratio of 0.04. Phreesia, Inc. has a 52 week low of $17.07 and a 52 week high of $29.16.

Phreesia (NYSE:PHR) last posted its quarterly earnings data on Monday, December 9th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.29) by $0.04. Phreesia had a negative return on equity of 32.78% and a negative net margin of 20.43%. The company had revenue of $106.80 million for the quarter, compared to the consensus estimate of $106.33 million. During the same quarter in the previous year, the business earned ($0.58) EPS. The company’s quarterly revenue was up 16.6% compared to the same quarter last year. On average, research analysts expect that Phreesia, Inc. will post -1.1 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, SVP Amy Beth Vanduyn sold 25,447 shares of the company’s stock in a transaction on Tuesday, December 3rd. The shares were sold at an average price of $20.93, for a total value of $532,605.71. Following the transaction, the senior vice president now directly owns 93,470 shares of the company’s stock, valued at approximately $1,956,327.10. This represents a 21.40 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this link. Also, COO Evan Roberts sold 2,681 shares of the firm’s stock in a transaction that occurred on Wednesday, January 8th. The shares were sold at an average price of $27.95, for a total transaction of $74,933.95. Following the transaction, the chief operating officer now directly owns 769,993 shares in the company, valued at approximately $21,521,304.35. The trade was a 0.35 % decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders sold 100,034 shares of company stock valued at $2,378,581. Company insiders own 5.80% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. Trust Point Inc. grew its position in Phreesia by 3.5% in the third quarter. Trust Point Inc. now owns 17,887 shares of the company’s stock valued at $408,000 after acquiring an additional 607 shares during the period. Ensign Peak Advisors Inc increased its position in shares of Phreesia by 3.2% during the 2nd quarter. Ensign Peak Advisors Inc now owns 22,491 shares of the company’s stock worth $477,000 after purchasing an additional 700 shares in the last quarter. The Manufacturers Life Insurance Company boosted its position in Phreesia by 3.3% in the third quarter. The Manufacturers Life Insurance Company now owns 27,935 shares of the company’s stock valued at $637,000 after buying an additional 905 shares in the last quarter. MetLife Investment Management LLC boosted its position in Phreesia by 3.8% in the third quarter. MetLife Investment Management LLC now owns 30,781 shares of the company’s stock valued at $701,000 after buying an additional 1,120 shares in the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank raised its stake in shares of Phreesia by 9.9% in the third quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 14,015 shares of the company’s stock valued at $319,000 after acquiring an additional 1,258 shares during the last quarter. Institutional investors own 92.10% of the company’s stock.

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.